News

On World Brain Tumor Day, we join the global effort to raise awareness for brain tumor patients and reaffirm our commitment to driving research forward and enhancing outcomes.

We are proud to support clinical studies in brain tumors, particularly in glioma research. Contributing to the development of new therapies and better diagnostics is at the core of what we do.
With our RANO Reading Support, fully integrated into the eCRF, we help ensure consistent, standardized, and reliable assessment of imaging data. This integration enhances data quality and supports more robust clinical trial results.

Together, we continue working towards a future where brain tumor patients benefit from faster diagnoses, better treatments, and improved care.

Multiple Sclerosis is a complex and evolving disease, where even the smallest changes in the brain can have significant clinical impact. Detecting these subtle changes early and reliably is key to accurate staging and effective treatment decisions.
Just imagine…
Identifying smouldering lesions in a brain MRI with just one click.

On World MS Day, we spotlight our research—bringing Voxel-Guided Morphometry into the mTRIAL® platform to enable precise, scalable, and accessible imaging analysis.

– Reliable detection of subtle disease progression
– Objective and reproducible imaging biomarkers
– Intuitive and efficient workflows for experts and researchers

Our shared goal is simple yet powerful:
– Transform complex neuroimaging data into actionable insights
– Support clinicians in making confident, informed decisions
– Ultimately improve outcomes for people living with MS

Today, we stand with the global MS community — raising awareness, fostering innovation, and working towards a future where technology helps us stay one step ahead of the disease.

We are pleased to welcome Adnan Khalid, a PhD Researcher from Universitat Rovira i Virgili, Spain, who has joined us for a research stay as part of the BosomShield Project.

During his stay, Adnan will contribute to research focused on breast cancer molecular subtype classification and the assessment of associated relapse risk. His expertise and research interests align strongly with the goals of the project, which aims to advance intelligent and reliable approaches for breast cancer analysis and decision support.

We look forward to a productive collaboration, meaningful knowledge exchange, and impactful research outcomes during his time her with us in Heidelberg.

Welcome, Adnan. We wish you a successful and inspiring research stay.

Excited to highlight another great achievement of our team:
Our PhD candidate Yaqeen Ali is first author of a publication on advancing AI‑based prediction of treatment response in breast cancer.

This study introduces a dual‑stream deep learning model that integrates both pre‑ and early‑treatment DCE‑MRI to predict pathological complete response (pCR). By combining spatial and temporal imaging information, the approach delivers improved predictive performance and provides valuable insights for more personalized therapy planning.

A strong step toward leveraging multimodal imaging and deep learning to support clinical decision‑making in breast cancer care.

Congratulations to the co-authors: Julia Müller, Tewele Weletnsea TAREKE. PhD., Alain Lalande, Fabrice Meriaudeau, Johannes Gregori!

Read the full article here

We are happy and proud to support Acandis in the conduct of the CARESTAR study.

The CARESTAR Study aims to evaluate the clinical safety and efficacy of the CARESTO® heal Stent in routine clinical practice for patients with symptomatic non-stenotic carotid disease (SyNC), a condition in which carotid arteries are narrowed by less than 50% but still exhibit high-risk features that can lead to recurrent stroke.

This prospective, randomised, multicenter, international study investigates whether stenting with the CARESTO® Heal stent in addition to optimal medical therapy is superior to optimal medical therapy alone in preventing future strokes. CARESTAR has the potential to identify the best treatment strategy and optimise future therapeutic approaches. We’re excited to share that the first patient has been recruited — an important milestone for the entire team.

Looking forward to the next five years of partnership, innovation, and progress.

Learn more about the CARESTO® Heal stent

Proud moment for our team. Our PhD candidate Yaqeen Ali has published new research on explainable and fair federated learning for predicting treatment response in breast cancer, together with Julia Müller, Andreas Weinmann, and Johannes Gregori.
Using the large multicenter MAMA‑MIA DCE‑MRI dataset, the study shows that federated XGBoost models can deliver strong performance, improved fairness, and full patient‑privacy preservation—supported by SHAP‑based interpretability.
A promising step toward collaborative, trustworthy AI in medical imaging.

 Read the full article here

On World Parkinson’s Day 2026, we stand behind this year’s call:
“It’s time for Europe to bridge the care gap and provide better support for people with Parkinson’s.”

We are committed to advancing brain‑health innovation. Our involvement in the EU‑funded AEGEUS project supports the development of a groundbreaking EEG–ultrasound device that combines high‑resolution EEG with functional ultrasound imaging to access both cortical and deep‑brain activity.

This novel wearable system aims to enable more accurate diagnostics and targeted, non‑invasive neurostimulation—technology that can ultimately pave the way for improved understanding and treatment of neurological diseases, including those impacting people with Parkinson’s disease.

We continue to contribute to evidence‑based technological innovation that supports more precise diagnostics and strengthens clinical decision‑making in neurological care.

Together for health. Stand with science.

Health thrives where people, technology, and science come together. On yersterday’s World Health Day, we at mediri want to highlight the essential role that scientific evidence plays in delivering modern, precise, and reliable healthcare.

Every day, our work reminds us:
Medical progress depends on data, research, and innovative technologies. It also depends on people collaborating to make diagnostics and therapy safer and more efficient. This is exactly what drives us — with our solutions for medical image analysis and AI‑supported evaluation.

We are proud to continue this journey with our partners, customers, and teams.

Excited to share our latest research publication! Our new paper, “Performance of federated versus centralized learning for mammography classification across film–digital domain shift”, is now published in Frontiers in Digital Health.

What’s it about? Deep learning in mammography relies on large, diverse datasets — but clinical data often remain siloed. Federated Learning (FL) offers a privacy-preserving alternative by enabling collaborative model training without sharing raw data. But how well does FL perform when imaging data come from very different domains, such as scanned film vs. digital mammography?

Key insights from our study:

• FL performs on par with centralized learning when all data come from similar domains.
• Under strong film–digital domain shift, FL maintains high performance on digital images but struggles on film-based data, showing reduced precision.
• Popular FL variants (FedAvg, FedProx, SCAFFOLD, FedBN) do not fully overcome this domain mismatch.
• Increasing image resolution helps but cannot close the performance gap.
• The findings highlight the need for domain-aware and personalized FL approaches to ensure safe, reliable deployment in breast imaging.

Why this matters: As healthcare moves toward privacy-preserving AI, understanding the limits of federated learning is crucial — especially in high-stakes applications like breast cancer detection.

Read the full article HERE

We’re proud to share a new scientific publication by our CEO, Prof. Matthias Guenther.

Understanding the earliest changes in the aging brain is essential for developing effective interventions against Alzheimer’s disease and vascular cognitive impairment. A newly published study featuring contributions from Prof. Matthias Günther and an international team of researchers sheds light on a promising biomarker: blood–brain barrier (BBB) water exchange.

Using a non‑invasive multi‑echo arterial spin labeling (ASL) technique, the study examined 160 adults aged 50+ across different cognitive stages. The findings reveal:

Key Highlights:
– Individuals with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) showed significantly reduced BBB water exchange time (Tex) compared to cognitively normal participants.

– Tex decreases appeared earlier than changes in traditional perfusion markers such as cerebral blood flow.

– BBB water exchange showed a stepwise decline with increasing cerebrovascular burden, indicating strong sensitivity to small vessel disease.

– After adjusting for age and sex, no association was found between Tex and amyloid positivity.

– These results suggest that vascular and neurovascular changes may precede amyloid‑related pathology in the trajectory of cognitive decline.

Why This Matters
BBB water exchange mapping could become a powerful, non‑invasive tool for detecting early neurovascular dysfunction—long before more overt symptoms or structural changes appear. This opens new possibilities for early diagnosis, risk stratification, and targeted intervention trials focusing on vascular contributions to dementia.

If you are interested in evaluating ASL or exploring how advanced perfusion imaging can support your research or clinical studies, feel free to reach out to us — we’re happy to discuss how we can support your work.

Read the full publication HERE